AstraZeneca gets DCGI approval for Dapagliflozin in treatment of heart failure
AstraZeneca Pharma India on Monday said it has received approval for extended indication from the Drugs Controller General of India for Dapagliflozin 10 mg tablets.
The receipt of this permission paves the way for the launch of the product in India for the specified indication, subject to the receipt of related statutory approvals and licenses. Image Courtesy: Reuters.